Global Non-Hodgkin Lymphoma Therapeutics Market 2023-2027
Description
Global Non-Hodgkin Lymphoma Therapeutics Market 2023-2027
Technavio has been monitoring the non-Hodgkin lymphoma therapeutics market and is forecast to grow by $5427.51 mn during 2022-2027, accelerating at a CAGR of 8.14% during the forecast period. Our report on the non-Hodgkin lymphoma therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by recent approvals and strong pipeline, growing geriatric population, and special drug designations.
Technavio's non-Hodgkin lymphoma therapeutics market is segmented as below:
By Distribution Channel
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the non-Hodgkin lymphoma therapeutics market covers the following areas:
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Technavio has been monitoring the non-Hodgkin lymphoma therapeutics market and is forecast to grow by $5427.51 mn during 2022-2027, accelerating at a CAGR of 8.14% during the forecast period. Our report on the non-Hodgkin lymphoma therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by recent approvals and strong pipeline, growing geriatric population, and special drug designations.
Technavio's non-Hodgkin lymphoma therapeutics market is segmented as below:
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
- Others
- Immunotherapy
- Targeted therapy
- Chemotherapy
- North America
- Europe
- Asia
- Rest of World (ROW)
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the non-Hodgkin lymphoma therapeutics market covers the following areas:
- Non-Hodgkin lymphoma therapeutics market sizing
- Non-Hodgkin lymphoma therapeutics market forecast
- Non-Hodgkin lymphoma therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
174 Pages
- Market overview
- Market ecosystem
- Market definition
- Market segment analysis
- Market size 2022
- Market outlook: Forecast for 2022-2027
- Global non-hodgkin lymphoma therapeutics market 2017 - 2021
- Therapy Segment Analysis 2017 - 2021
- Distribution channel Segment Analysis 2017 - 2021
- Geography Segment Analysis 2017 - 2021
- Country Segment Analysis 2017 - 2021
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segments
- Comparison by Distribution Channel
- Hospital pharmacy - Market size and forecast 2022-2027
- Retail pharmacy - Market size and forecast 2022-2027
- Online pharmacy - Market size and forecast 2022-2027
- Others - Market size and forecast 2022-2027
- Market opportunity by Distribution Channel
- Market segments
- Comparison by Therapy
- Immunotherapy - Market size and forecast 2022-2027
- Targeted therapy - Market size and forecast 2022-2027
- Chemotherapy - Market size and forecast 2022-2027
- Market opportunity by Therapy
- Customer landscape overview
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2022-2027
- Europe - Market size and forecast 2022-2027
- Asia - Market size and forecast 2022-2027
- Rest of World (ROW) - Market size and forecast 2022- 2027
- US - Market size and forecast 2022-2027
- UK - Market size and forecast 2022-2027
- Germany - Market size and forecast 2022-2027
- China - Market size and forecast 2022-2027
- Canada - Market size and forecast 2022-2027
- Market opportunity by geography
- Market drivers
- Market challenges
- Impact of drivers and challenges
- Market trends
- Overview
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- AstraZeneca Plc
- BeiGene Ltd.
- Biogen Inc.
- Bristol Myers Squibb Co.
- Eisai Co. Ltd.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Seagen Inc.
- Spectrum Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- Scope of the report
- Inclusions and exclusions checklist
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
